Korro Bio vs Ovid Therapeutics
KRRO and OVID side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KRRO and OVID compare
Ovid Therapeutics is the larger company, worth 2.5 times as much as Korro Bio ($469M against $187M).
Korro Bio grew revenue faster over the last twelve months (−62.1% versus −76.2% for Ovid Therapeutics).
Ovid Therapeutics keeps more of each dollar of sales as profit, with a net margin of −2179% compared with −4477% at Korro Bio.
Ovid Therapeutics scores higher on the StockData Score (9 against 5 for Korro Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KRRO | OVID |
|---|---|---|
| Size and price | ||
| Market cap | $187M | $469M |
| Share price | $12.71 | $2.40 |
| Change, 1 year | 95.5% | 100% |
| Change, 5 years | −95.5% | −26.4% |
| Beta (5Y) | 2.43 | 1.24 |
| Employees | 58 | 23 |
| StockData Score | ||
| Total score | 5 | 9 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 78.6× (better) | 296× |
| P/B | – | 2.2× |
| FCF yield | −36.5% | – |
| Growth | ||
| Revenue growth (TTM) | −62.1% (better) | −76.2% |
| Revenue growth, 5Y average | −29.6% | −10.5% (better) |
| Profitability | ||
| Operating margin | −4625% | −3687% (better) |
| Net margin | −4477% | −2179% (better) |
| FCF margin | −2866% | – |
| Return on equity | – | −26.0% |
| Return on invested capital | – | −160% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 9.55 | 12.39 (better) |
| Altman Z-score | −3.17 | 10.36 (better) |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 102% | 75.3% |
| Held by insiders | 27.4% | 13.6% |
| Insider net buying, 12 months | $15.0M (better) | −$29.3K |
| Short interest, % of float | 16.4% | 10.8% |
Go deeper
- KRRO stock overview
- KRRO income statement
- KRRO valuation and score
- OVID stock overview
- OVID income statement
- OVID valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.